A Phase 1/2 interventional study of mRNA-1073 and mRNA-1010 in SARS-CoV-2 and Influenza, sponsored by ModernaTX, Inc.. Completed at 14 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-28.
Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human — 2 open to participants now, 2 under way, none of them phase 3. mRNA-1010 influenza vaccine · Influenza, Human.
Among the 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human, this one is the 6th largest by enrollment, is one of 6 that started in 2022, is one of 2 in phase 1/2, and was the 2nd registered.
2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.
Browse Influenza, Human studies →2 of the 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human are open now, in 1 country. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in United States
Ages 65+ · Healthy volunteers
ModernaTX, Inc. · Sites in United States
Ages 9–17 · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 4 · Phase 3 4 · Phase 4 1
First in 2021; this study’s year is marked. 6 started in 2022.
This study's enrollment of 550 is above the median of 228 across 1,959 interventional studies indexed under Influenza, Human.
Median enrollment 471 across the 12 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 1 most frequent:
This study is registered under ModernaTX, Inc., one of the names counted as Moderna, Inc.. Under that name alone:
ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.
Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.
23 studies in Influenza, Human by Moderna, Inc.: 2 open now, 3 under way, 1 of them phase 3. Of 20 finished, 12 (60%) have results posted.
Among the 23 studies in Influenza, Human by Moderna, Inc., this one is the 15th largest by enrollment, is one of 7 that started in 2022, is one of 6 in phase 1/2, and was the 5th registered.
Moderna, Inc.’s Influenza, Human studies by the year they started, since 2015.
1 of the studies testing mRNA-1010 influenza vaccine in Influenza, Human that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07884175ModernaTX, Inc.A Study of Updated mRNA Seasonal Influenza Vaccines | 2026-12-07 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human, from their registry updates:
Among Moderna, Inc.’s 23 in Influenza, Human:
This tab as a report to print or save as PDF → With an account.
The primary goal of this study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1073 compared to co-administered mRNA-1010 and mRNA-1273 vaccines and to the individual vaccines alone in healthy participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Phase 1 Specific Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 2 intramuscular (IM) injections, one in each arm, of mRNA-1273 plus placebo at the specified dose level on Day 1.
Biological: mRNA-1273 · Biological: Placebo
Participants will receive 2 IM injections, one in each arm, of mRNA-1010 plus placebo at the specified dose level on Day 1.
Biological: mRNA-1010 · Biological: Placebo
Participants will receive 2 IM injections, one in each arm, of mRNA-1010 plus mRNA-1273 at the specified dose level on Day 1.
Biological: mRNA-1010
Participants will receive 2 IM injections, one in each arm, of mRNA-1073 plus placebo at the specified dose level on Day 1.
Biological: mRNA-1073 · Biological: Placebo
Participants will receive 2 IM injections, one in each arm, of mRNA-1073 plus placebo at the specified dose level on Day 1.
Biological: mRNA-1073 · Biological: Placebo
Participants will receive 2 IM injections, one in each arm, of mRNA-1073 plus placebo at the specified dose level on Day 1.
Biological: mRNA-1073 · Biological: Placebo
Number of Participants With Solicited Local and Systemic Adverse Reaction (ARs)
Solicited ARs (local and systemic) were collected in the electronic diary (eDiary). Local ARs included: pain at injection site, erythema (redness) at injection site, swelling/induration (hardness) at injection site, and localized axillary swelling or tenderness ipsilateral to the injection arm. Systemic ARs included: headache, fatigue, myalgia (muscle aches all over the body), arthralgia (aching in several joints), nausea/vomiting, rash, body temperature (potentially fever), and chills. Note, that not all solicited ARs were considered adverse events (AEs). The Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of all serious AEs (SAEs) and all nonserious AEs ("Other"), regardless of causality, is in Reported "Adverse Events" section.
Time frame: Up to Day 8 (7 days post vaccination)
Number of Participants With Unsolicited Adverse Events (AEs)
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. A treatment-emergent AE (TEAE) was defined as any event not present before exposure to vaccine or any event already present that worsens in intensity or frequency after exposure. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsens from baseline and is considered clinically significant in the medical and scientific judgment of the Investigator. A summary of SAEs and all nonserious AEs ("Other") reported up to the end of the study, regardless of causality, is located in the Reported "Adverse Events" section.
Time frame: Up to Day 29 (28 days post vaccination)
Number of Participants With Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs), Medically-Attended AEs (MAAEs) and AEs Leading to Discontinuation
An SAE was defined as any AE that resulted in death, is life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/permanent damage, was a congenital anomaly/birth defect, or was an important medical event. AESIs included thrombocytopenia, new onset of or worsening of the protocol specified neurologic diseases, anaphylaxis, and myocarditis/pericarditis. An MAAE is an AE that leads to an unscheduled visit to a healthcare practitioner. This would include visits to a study site for unscheduled assessments (for example, abnormal laboratory follow-up, and/or COVID-19 and visits to healthcare practitioners external to the study site (for example, urgent care, primary care physician). A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.
Time frame: Up to Day 181
Geometric Mean Titer of Anti-Hemagglutinin Antibodies at Day 29, as Measured by Hemagglutination Inhibition Assay (HAI) For Vaccine-Matched Seasonal Influenza A and B Strains
Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included BV and BY.
Time frame: Day 29
Geometric Mean Titer of VAC62 Neutralizing Antibody at Day 29, as Measured by Pseudovirus Neutralization Assay (or Binding Antibody Assay) For Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Time frame: Day 29
Geometric Mean Fold Rise of Anti-Hemagglutinin Antibodies at Day 29, as Measured by Hemagglutination Inhibition Assay (HAI) For Vaccine-Matched Seasonal Influenza A and B Strains
Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included BV and BY.
Time frame: Day 29
Geometric Mean Fold Rise of VAC62 Neutralizing Antibody at Day 29, as Measured by Pseudovirus Neutralization Assay (or Binding Antibody Assay) For SARS-CoV-2
The GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. 95% CI was calculated based on the difference in the log-transformed values for GMFR, then back transformed to the original scale for presentation.
Time frame: Day 29
Percentage of Participants With Seroconversion as Measured by HAI Assay For Vaccine-Matched Seasonal Influenza A and B Strains
Seroconversion at a participant level is defined as a pre-vaccination HAI titer \< 1:10 and a post-vaccination HAI titer \>= 1:40 or a pre-vaccination HAI titer \>= 1:10 and a minimum 4-fold rise in post vaccination HAI antibody titer.
Time frame: Day 29
Percentage of Participants With Seroresponse as Measured by PsVNA (or Binding Antibody Assay) For SARS-CoV-2
Seroresponse at a participant level is defined as an increase from below the lower limit of quantification (LLOQ) to \>= 4 x LLOQ if baseline neutralizing antibody (nAb) level is \< LLOQ, or \>= 4 fold rise if baseline nAb level is \>=LLOQ.
Time frame: Day 29
| Milestone | mRNA-1273 + Placebo | mRNA-1010 + Placebo | mRNA-1010 + mRNA-1273 | Dose A: mRNA-1073 Low Dose + Placebo | Dose B: mRNA-1073 Medium Dose + Placebo | Dose C: mRNA-1073 High Dose + Placebo |
|---|---|---|---|---|---|---|
| Started | 50 | 99 | 101 | 100 | 100 | 100 |
| Received at least 1 dose of study drug | 49 | 99 | 101 | 100 | 98 | 100 |
| Completed | 46 | 90 | 98 | 93 | 94 | 96 |
| Not completed | 4 | 9 | 3 | 7 | 6 | 4 |
| Withdrew: Other | 0 | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 1 | 3 | 2 | 2 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 2 | 7 | 0 | 4 | 2 | 3 |
Solicited ARs (local and systemic) were collected in the electronic diary (eDiary). Local ARs included: pain at injection site, erythema (redness) at injection site, swelling/induration (hardness) at injection site, and localized axillary swelling or tenderness ipsilateral to the injection arm. Systemic ARs included: headache, fatigue, myalgia (muscle aches all over the body), arthralgia (aching in several joints), nausea/vomiting, rash, body temperature (potentially fever), and chills. Note, that not all solicited ARs were considered adverse events (AEs). The Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of all serious AEs (SAEs) and all nonserious AEs ("Other"), regardless of causality, is in Reported "Adverse Events" section.
| Participants | mRNA-1273 + Placebo | mRNA-1010 + Placebo | mRNA-1010 + mRNA-1273 | Dose A: mRNA-1073 Low Dose + Placebo | Dose B: mRNA-1073 Medium Dose + Placebo | Dose C: mRNA-1073 High Dose + Placebo |
|---|---|---|---|---|---|---|
| Solicited Local ARs | 38 | 80 | 90 | 92 | 76 | 78 |
| Solicited Systemic ARs | 31 | 70 | 87 | 80 | 63 | 67 |
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. A treatment-emergent AE (TEAE) was defined as any event not present before exposure to vaccine or any event already present that worsens in intensity or frequency after exposure. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsens from baseline and is considered clinically significant in the medical and scientific judgment of the Investigator. A summary of SAEs and all nonserious AEs ("Other") reported up to the end of the study, regardless of causality, is located in the Reported "Adverse Events" section.
| Participants | mRNA-1273 + Placebo | mRNA-1010 + Placebo | mRNA-1010 + mRNA-1273 | Dose A: mRNA-1073 Low Dose + Placebo | Dose B: mRNA-1073 Medium Dose + Placebo | Dose C: mRNA-1073 High Dose + Placebo |
|---|---|---|---|---|---|---|
| Number of Participants With Unsolicited Adverse Events (AEs) | 7 | 21 | 14 | 19 | 11 | 22 |
An SAE was defined as any AE that resulted in death, is life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/permanent damage, was a congenital anomaly/birth defect, or was an important medical event. AESIs included thrombocytopenia, new onset of or worsening of the protocol specified neurologic diseases, anaphylaxis, and myocarditis/pericarditis. An MAAE is an AE that leads to an unscheduled visit to a healthcare practitioner. This would include visits to a study site for unscheduled assessments (for example, abnormal laboratory follow-up, and/or COVID-19 and visits to healthcare practitioners external to the study site (for example, urgent care, primary care physician). A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.
| Participants | mRNA-1273 + Placebo | mRNA-1010 + Placebo | mRNA-1010 + mRNA-1273 | Dose A: mRNA-1073 Low Dose + Placebo | Dose B: mRNA-1073 Medium Dose + Placebo | Dose C: mRNA-1073 High Dose + Placebo |
|---|---|---|---|---|---|---|
| SAEs | 2 | 1 | 0 | 0 | 1 | 0 |
| AESIs | 0 | 2 | 0 | 1 | 0 | 1 |
| MAAEs | 13 | 38 | 32 | 34 | 34 | 44 |
| AEs leading to discontinuation | 0 | 0 | 0 | 0 | 0 | 0 |
Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included BV and BY.
| titer | mRNA-1010 + Placebo | mRNA-1010 + mRNA-1273 | Dose A: mRNA-1073 Low Dose + Placebo | Dose B: mRNA-1073 Medium Dose + Placebo | Dose C: mRNA-1073 High Dose + Placebo |
|---|---|---|---|---|---|
| Influenza A H1N1 Antibody | 175.41 (139.67 to 220.30) | 134.04 (110.72 to 162.26) | 104.78 (82.94 to 132.39) | 111.33 (90.94 to 136.29) | 108.68 (88.64 to 133.26) |
| Influenza A H3N2 Antibody | 189.9 (145.67 to 247.54) | 214.12 (171.36 to 267.56) | 144.36 (111.87 to 186.29) | 141.15 (112.68 to 176.80) | 129.94 (103.77 to 162.715) |
| Influenza B BV Antibody | 106.22 (89.66 to 125.83) | 107.91 (92.79 to 125.50) | 91.78 (77.16 to 109.16) | 89.27 (75.92 to 104.98) | 84.82 (72.56 to 99.15) |
| Influenza B BY Antibody | 194.51 (163.21 to 231.81) | 182.01 (152.26 to 217.58) | 139.48 (112.70 to 172.61) | 130.27 (107.67 to 157.61) | 121.29 (99.73 to 147.52) |
| titer | mRNA-1273 + Placebo | mRNA-1010 + mRNA-1273 | Dose A: mRNA-1073 Low Dose + Placebo | Dose B: mRNA-1073 Medium Dose + Placebo | Dose C: mRNA-1073 High Dose + Placebo |
|---|---|---|---|---|---|
| Geometric Mean Titer of VAC62 Neutralizing Antibody at Day 29, as Measured by Pseudovirus Neutralization Assay (or Binding Antibody Assay) For Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) | 8477.30 (6424.05 to 11186.62) | 6075.76 (5119.62 to 7210.47) | 7573.97 (6475.43 to 8858.86) | 5678.54 (4671.74 to 6902.32) | 4410.29 (3762.65 to 5169.41) |
Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included BV and BY.
| ratio | mRNA-1010 + Placebo | mRNA-1010 + mRNA-1273 | Dose A: mRNA-1073 Low Dose + Placebo | Dose B: mRNA-1073 Medium Dose + Placebo | Dose C: mRNA-1073 High Dose + Placebo |
|---|---|---|---|---|---|
| Influenza A H1N1 Antibody | 3.97 (3.19 to 4.95) | 3.31 (2.76 to 3.96) | 2.25 (1.89 to 2.68) | 2.48 (2.06 to 2.98) | 2.67 (2.21 to 3.23) |
| Influenza A H3N2 Antibody | 5.82 (4.56 to 7.43) | 5.07 (4.19 to 6.14) | 3.84 (3.22 to 4.58) | 4.15 (3.33 to 5.18) | 3.41 (2.80 to 4.14) |
| Influenza B BV Antibody | 1.61 (1.42 to 1.82) | 1.64 (1.47 to 1.84) | 1.29 (1.14 to 1.44) | 1.29 (1.18 to 1.43) | 1.29 (1.16 to 1.43) |
| Influenza B BY Antibody | 2.68 (2.25 to 3.19) | 2.17 (1.85 to 2.53) | 1.63 (1.46 to 1.83) | 1.65 (1.46 to 1.87) | 1.58 (1.41 to 1.78) |
The GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. 95% CI was calculated based on the difference in the log-transformed values for GMFR, then back transformed to the original scale for presentation.
| ratio | mRNA-1273 + Placebo | mRNA-1010 + mRNA-1273 | Dose A: mRNA-1073 Low Dose + Placebo | Dose B: mRNA-1073 Medium Dose + Placebo | Dose C: mRNA-1073 High Dose + Placebo |
|---|---|---|---|---|---|
| Geometric Mean Fold Rise of VAC62 Neutralizing Antibody at Day 29, as Measured by Pseudovirus Neutralization Assay (or Binding Antibody Assay) For SARS-CoV-2 | 6.14 (3.98 to 9.48) | 4.07 (3.26 to 5.07) | 3.50 (2.76 to 4.44) | 3.45 (2.82 to 4.22) | 3.18 (2.73 to 3.69) |
Seroconversion at a participant level is defined as a pre-vaccination HAI titer \< 1:10 and a post-vaccination HAI titer \>= 1:40 or a pre-vaccination HAI titer \>= 1:10 and a minimum 4-fold rise in post vaccination HAI antibody titer.
| percentage of participants | mRNA-1010 + Placebo | mRNA-1010 + mRNA-1273 | Dose A: mRNA-1073 Low Dose + Placebo | Dose B: mRNA-1073 Medium Dose + Placebo | Dose C: mRNA-1073 High Dose + Placebo |
|---|---|---|---|---|---|
| Influenza A H1N1 Antibody | 47.1 (36.3 to 58.1) | 42.6 (32.4 to 53.2) | 27.5 (18.6 to 37.8) | 31.4 (21.8 to 42.3) | 31.6 (22.4 to 41.9) |
| Influenza A H3N2 Antibody | 64.4 (53.4 to 74.4) | 63.8 (53.3 to 73.5) | 53.8 (43.1 to 64.4) | 53.5 (42.4 to 64.3) | 42.1 (32.0 to 52.7) |
| Influenza B BV Antibody | 16.1 (9.1 to 25.5) | 9.6 (4.5 to 17.4) | 3.3 (0.7 to 9.3) | 2.3 (0.3 to 8.1) | 6.3 (2.4 to 13.2) |
| Influenza B BY Antibody | 32.2 (22.6 to 43.1) | 19.1 (11.8 to 28.6) | 11.0 (5.4 to 19.3) | 10.5 (4.9 to 18.9) | 10.5 (5.2 to 18.5) |
Seroresponse at a participant level is defined as an increase from below the lower limit of quantification (LLOQ) to \>= 4 x LLOQ if baseline neutralizing antibody (nAb) level is \< LLOQ, or \>= 4 fold rise if baseline nAb level is \>=LLOQ.
| percentage of participants | mRNA-1273 + Placebo | mRNA-1010 + mRNA-1273 | Dose A: mRNA-1073 Low Dose + Placebo | Dose B: mRNA-1073 Medium Dose + Placebo | Dose C: mRNA-1073 High Dose + Placebo |
|---|---|---|---|---|---|
| Percentage of Participants With Seroresponse as Measured by PsVNA (or Binding Antibody Assay) For SARS-CoV-2 | 52.4 (36.4 to 68.0) | 44.4 (34.0 to 55.3) | 37.5 (27.4 to 48.5) | 36.5 (26.3 to 47.6) | 35.9 (26.1 to 46.5) |
Collected over Day 1 through Day 181. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| mRNA-1273 + Placebo | 0/49 (0%) | 2/49 (4.1%) | 42/49 (85.7%) |
| mRNA-1010 + Placebo | 0/99 (0%) | 1/99 (1%) | 86/99 (86.9%) |
| mRNA-1010 + mRNA-1273 | 0/101 (0%) | 0/101 (0%) | 93/101 (92.1%) |
| Dose A: mRNA-1073 Low Dose + Placebo | 0/100 (0%) | 0/100 (0%) | 94/100 (94%) |
| Dose B: mRNA-1073 Medium Dose + Placebo | 0/98 (0%) | 1/98 (1%) | 81/98 (82.7%) |
| Dose C: mRNA-1073 High Dose + Placebo | 0/100 (0%) | 0/100 (0%) | 89/100 (89%) |
| Event | mRNA-1273 + Placebo | mRNA-1010 + Placebo | mRNA-1010 + mRNA-1273 | Dose A: mRNA-1073 Low Dose + Placebo | Dose B: mRNA-1073 Medium Dose + Placebo | Dose C: mRNA-1073 High Dose + Placebo |
|---|---|---|---|---|---|---|
| Cardiac failure congestiveCardiac disorders | 1/49 | 0/99 | 0/101 | 0/100 | 0/98 | 0/100 |
| Urinary tract infectionInfections and infestations | 1/49 | 0/99 | 0/101 | 0/100 | 0/98 | 0/100 |
| Septic shockInfections and infestations | 0/49 | 0/99 | 0/101 | 0/100 | 1/98 | 0/100 |
| Plasma cell myelomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/49 | 0/99 | 0/101 | 0/100 | 1/98 | 0/100 |
| Tibia fractureInjury, poisoning and procedural complications | 0/49 | 1/99 | 0/101 | 0/100 | 0/98 | 0/100 |
| Event | mRNA-1273 + Placebo | mRNA-1010 + Placebo | mRNA-1010 + mRNA-1273 | Dose A: mRNA-1073 Low Dose + Placebo | Dose B: mRNA-1073 Medium Dose + Placebo | Dose C: mRNA-1073 High Dose + Placebo |
|---|---|---|---|---|---|---|
| Injection site painGeneral disorders | 38/49 | 80/99 | 89/101 | 91/100 | 76/98 | 78/100 |
| FatigueGeneral disorders | 25/49 | 57/99 | 79/101 | 67/100 | 45/98 | 51/100 |
| MyalgiaMusculoskeletal and connective tissue disorders | 20/49 | 52/99 | 73/101 | 59/100 | 42/98 | 41/100 |
| HeadacheNervous system disorders | 18/49 | 41/99 | 64/101 | 63/100 | 42/98 | 45/100 |
| ChillsGeneral disorders | 10/49 | 31/99 | 51/101 | 46/100 | 30/98 | 20/100 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 17/49 | 30/99 | 49/101 | 49/100 | 35/98 | 31/100 |
| Injection site lymphadenopathyGeneral disorders | 15/49 | 19/99 | 25/101 | 26/100 | 20/98 | 22/100 |
| VomitingGastrointestinal disorders | 7/49 | 14/99 | 23/101 | 14/100 | 14/98 | 6/100 |
| PyrexiaGeneral disorders | 2/49 | 4/99 | 20/101 | 17/100 | 5/98 | 2/100 |
| COVID-19Infections and infestations | 3/49 | 14/99 | 11/101 | 13/100 | 13/98 | 18/100 |
The Full analysis set consisted of all randomly assigned participants who received the investigational product (IP). Participants were analyzed according to the group to which they were randomized.
| Age, Continuous(years) | mRNA-1273 + Placebo | mRNA-1010 + Placebo | mRNA-1010 + mRNA-1273 | Dose A: mRNA-1073 Low Dose + Placebo | Dose B: mRNA-1073 Medium Dose + Placebo | Dose C: mRNA-1073 High Dose + Placebo | Total |
|---|---|---|---|---|---|---|---|
| Mean | 47.8 ± 15.37 | 47.4 ± 14.49 | 48.5 ± 14.55 | 49.3 ± 15.10 | 49.0 ± 13.93 | 48.2 ± 14.54 | 48.4 ± 14.55 |
| Sex: Female, Male(Participants) | mRNA-1273 + Placebo | mRNA-1010 + Placebo | mRNA-1010 + mRNA-1273 | Dose A: mRNA-1073 Low Dose + Placebo | Dose B: mRNA-1073 Medium Dose + Placebo | Dose C: mRNA-1073 High Dose + Placebo | Total |
|---|---|---|---|---|---|---|---|
| Female | 29 | 54 | 65 | 55 | 56 | 64 | 323 |
| Male | 20 | 45 | 36 | 45 | 42 | 36 | 224 |
| Ethnicity (NIH/OMB)(Participants) | mRNA-1273 + Placebo | mRNA-1010 + Placebo | mRNA-1010 + mRNA-1273 | Dose A: mRNA-1073 Low Dose + Placebo | Dose B: mRNA-1073 Medium Dose + Placebo | Dose C: mRNA-1073 High Dose + Placebo | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 11 | 14 | 11 | 8 | 7 | 54 |
| Not Hispanic or Latino | 42 | 88 | 85 | 88 | 88 | 92 | 483 |
| Unknown or Not Reported | 4 | 0 | 2 | 1 | 2 | 1 | 10 |
| Race (NIH/OMB)(Participants) | mRNA-1273 + Placebo | mRNA-1010 + Placebo | mRNA-1010 + mRNA-1273 | Dose A: mRNA-1073 Low Dose + Placebo | Dose B: mRNA-1073 Medium Dose + Placebo | Dose C: mRNA-1073 High Dose + Placebo | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 | 0 | 1 | 0 | 3 |
| Asian | 0 | 2 | 5 | 3 | 4 | 3 | 17 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Black or African American | 11 | 13 | 8 | 17 | 16 | 13 | 78 |
| White | 37 | 83 | 85 | 79 | 76 | 83 | 443 |
| More than one race | 0 | 0 | 2 | 0 | 1 | 0 | 3 |
| Unknown or Not Reported | 1 | 0 | 0 | 0 | 0 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2022 to primary completion in Dec 2022, 7 months.
Results were first posted in Feb 2024, 1 year 1 month after primary completion.
Of 41 industry-sponsored phase 1/2 interventional studies under Influenza, Human, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's 7 months is below that.
Counting every sponsor, half of 43 studies reached it within 12 months; a quarter within 7 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: mRNA-1010 influenza vaccine · 2019-nCoV Vaccine mRNA-1273